MARLBOROUGH, Mass.,
Feb. 7, 2017 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi
company developing innovative therapeutics that address significant
unmet medical needs, today announced the appointment of Dr.
Rolf Kiessling, Professor in
Experimental Oncology at Karolinska
Institutet to its Scientific Advisory Board. Dr.
Kiessling also serves as Senior Chief Physician of Radiumhemmet at
Karolinska Hospital.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
"This is an exciting time for RXi Pharmaceuticals as they expand
development efforts using their proprietary self-delivering RNAi
technology in the field of cell-based immunotherapy," said Dr.
Rolf Kiessling. He further
added that, "I welcome the opportunity to work with the
accomplished team of advisors at RXi and look forward to being a
part of their mission to develop innovative therapeutics to improve
patients' lives."
Dr. Kiessling has broad scientific expertise in the field of
experimental and clinical immunology and accredited with the
discovery for Natural Killer cells (NK cells) during the mid-70's.
He has published more than 250 publications in peer-reviewed
journals. Professor Kiessling has served as a Member of the
Research Council at the Swedish Cancer Society and the Swedish
Association for Medical Research.
"We are honored to have Dr. Kiessling join our Scientific
Advisory Board," said Dr. Pamela
Pavco, Chief Development Officer of RXi Pharmaceuticals. "He
brings a wealth of invaluable insight and guidance as we pursue the
development of cell-based immuno-oncology therapeutics, in addition
to our dermatology and ophthalmology programs."
About RXi's Proprietary Self-delivering RNAi (sd-rxRNA)
Technology Platform
RXi's proprietary sd-rxRNA technology has many advantages over
its competitors in the RNAi space. Scientists at RXi have
designed chemically-modified RNAi compounds with improved drug-like
properties that are potent, stable and specific. These
proprietary compounds have built-in delivery properties and
therefore do not require a delivery vehicle for local therapeutic
applications. The enhanced properties of sd-rxRNA
include: efficient spontaneous cellular uptake, stability,
reduced potential for immune stimulation, and potent, long-lasting
intracellular activity. All cell types tested (primary,
neuronal and non-adherent) internalize sd-rxRNA compounds uniformly
and efficiently, resulting in potent and long lasting
silencing. sd‑rxRNA compounds have the ability to selectively
block the expression of any target in the genome, thus providing
applicability to a broad spectrum of therapeutic areas.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage company developing innovative therapeutics that
address significant unmet medical needs. Building on the
pioneering discovery of RNAi, scientists at RXi Company have
harnessed the naturally occurring RNAi process which has the
ability to "silence" or down-regulate the expression of a specific
gene that may be overexpressed in a disease condition. RXi
developed a robust RNAi therapeutic platform including
self-delivering RNA (sd-rxRNA®) compounds, that have the ability to
highly selectively block the expression of any target in the
genome, thus providing applicability to a broad spectrum of
therapeutic areas. Our current programs include dermatology,
ophthalmology and cell-based immunotherapy. RXi's extensive
patent portfolio provides for multiple product and business
development opportunities across a broad spectrum of therapeutic
areas and we actively pursue research collaborations, partnering
and out-licensing opportunities with academia and pharmaceutical
companies. Additional information may be found on the
Company's website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-appoints-leading-oncology-expert-dr-rolf-kiessling-to-scientific-advisory-board-300403137.html
SOURCE RXi Pharmaceuticals Corporation